Virginia Kaklamani
19PUBLICATIONS
82CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (19)
Sort by Publication Date:
|Nov 14, 2025
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.Hope S Rugo, Virginia Kaklamani, Heather McArthur
|May 21, 2025
Treatment Patterns of Goserelin 3.6 mg Once Every 4 Weeks and 10.8 mg Once Every 12 Weeks in Women With Breast Cancer: A Real-World Analysis of Patients in the United States.Kelly E McCann, Virginia Kaklamani, Noran Osman
|Apr 15, 2025
Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.Ranjit Banwait, Heidi Ko, Joel Michalek
|Mar 06, 2025
Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study.Kelly E McCann, Noran Osman, Joan Cannon
|Oct 01, 2024
Breast cancer: The good, the bad, and an important call to effective risk reduction strategies.Virginia G Kaklamani, Carlos L Arteaga
|Aug 01, 2024
Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.Aditya Bardia, Javier Cortés, François-Clément Bidard
Pageof 4
Frequent Collaborators
4 joint publications
Aditya Bardia
3 joint publications
Marisa Weiss
3 joint publications
Rowen Chlebowski
2 joint publications
Tomer Wasserman
2 joint publications
Kelly E McCann
2 joint publications
Ismail Jatoi
2 joint publications
Noran Osman
2 joint publications
Javier Cortés
2 joint publications
Phillipe Aftimos
1 joint publications
Byeong Yeob Choi
